Aclaris Therapeutics (ACRS) Corporate presentation summary

Corporate strategy and market opportunity

• Multiple clinical programs are ongoing, with additional IND expected in 2026, targeting validated immune and inflammatory disease pathways.

• Focus on oral and antibody therapeutics, including bispecific and ITK inhibitors, aiming for paradigm shifts in treatment.

• Addressable market for immune and inflammatory diseases exceeds 1 billion people globally, with significant unmet needs in dermatology and respiratory indications.

• Total addressable market for Th1, Th2, and Th17-mediated diseases projected to reach up to $70B globally by 2034.

• Commercial strategy emphasizes innovative drugs to fill gaps in efficacy, safety, and convenience for both oral and antibody therapies.

Pipeline and development highlights

• Bosakitug (ATI-045), a highly differentiated anti-TSLP antibody, shows best-in-class potential with extended dosing intervals and superior potency compared to marketed competitors.

• ATI-052, a first-generation bispecific antibody targeting TSLP and IL-4Ra, demonstrates high potency, long residence time, and potential for quarterly dosing.

• ATI-2138, a novel ITK/JAK3 inhibitor, exhibits strong efficacy in preclinical and clinical studies for atopic dermatitis and is advancing to Phase 2b for lichen planus.

• Next-generation multispecific and JAK-sparing ITK inhibitors are progressing toward IND, aiming to expand therapeutic options and improve safety profiles.

Clinical results and milestones

• Bosakitug achieved high rates of EASI-75 and EASI-90 responses in Phase 2a atopic dermatitis trials, with sustained efficacy and favorable safety.

• ATI-052 Phase 1 SAD/MAD studies in healthy volunteers showed robust pharmacokinetics, sustained pharmacodynamic inhibition, and a strong safety profile.

• ATI-2138 demonstrated rapid and sustained efficacy in atopic dermatitis, with significant improvements in itch and disease severity, and strong downregulation of inflammatory pathways.

• Multiple clinical milestones are anticipated in 2026, including top-line results for ongoing Phase 2 and 1b trials and initiation of new Phase 2b programs.